Wedbush Equities Analysts Lift Earnings Estimates for BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at Wedbush increased their Q1 2026 earnings per share estimates for BioCryst Pharmaceuticals in a report issued on Monday, June 30th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.18 for the quarter, up from their previous forecast of $0.11. Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q4 2026 earnings at $0.25 EPS, FY2027 earnings at $0.79 EPS and FY2029 earnings at $1.07 EPS.

Other research analysts have also recently issued research reports about the company. Barclays raised their target price on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Bank of America increased their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. increased their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, June 25th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.70.

BioCryst Pharmaceuticals Stock Down 0.8%

Shares of BCRX stock opened at $8.95 on Wednesday. The stock has a 50-day simple moving average of $10.04 and a 200 day simple moving average of $8.59. BioCryst Pharmaceuticals has a fifty-two week low of $6.02 and a fifty-two week high of $11.31. The stock has a market capitalization of $1.87 billion, a P/E ratio of -34.40, a P/E/G ratio of 2.58 and a beta of 1.04.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Doliver Advisors LP boosted its position in BioCryst Pharmaceuticals by 269.1% during the 2nd quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company’s stock worth $2,458,000 after acquiring an additional 200,000 shares during the period. Rhumbline Advisers boosted its position in BioCryst Pharmaceuticals by 3.9% during the 1st quarter. Rhumbline Advisers now owns 321,154 shares of the biotechnology company’s stock worth $2,409,000 after acquiring an additional 12,022 shares during the period. Strs Ohio acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth about $284,000. Acadian Asset Management LLC boosted its position in BioCryst Pharmaceuticals by 244.1% during the 1st quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company’s stock worth $5,023,000 after acquiring an additional 475,564 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after acquiring an additional 47,355 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.